Media stories about Valeant Pharmaceuticals International (NYSE:VRX) (TSE:VRX) have trended somewhat positive recently, Accern Sentiment reports. The research firm scores the sentiment of press coverage by analyzing more than 20 million blog and news sources in real time. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. Valeant Pharmaceuticals International earned a coverage optimism score of 0.15 on Accern’s scale. Accern also gave news stories about the specialty pharmaceutical company an impact score of 44.8670675204531 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the near future.
These are some of the news stories that may have effected Accern Sentiment’s analysis:
- BMO Capital Markets Reaffirms Hold Rating for Valeant Pharmaceuticals International (VRX) (americanbankingnews.com)
- Royal Bank of Canada Increases Valeant Pharmaceuticals International (VRX) Price Target to $21.00 (americanbankingnews.com)
- Valeant Pharmaceuticals International (VRX) PT Set at $14.00 by Piper Jaffray (americanbankingnews.com)
- Valeant Pharmaceuticals International (VRX) PT Set at $17.00 by HC Wainwright (americanbankingnews.com)
- Valeant Pharmaceuticals International (VRX) Given a $14.00 Price Target by Canaccord Genuity Analysts (americanbankingnews.com)
VRX has been the topic of a number of research analyst reports. Deutsche Bank set a $20.00 price target on shares of Valeant Pharmaceuticals International and gave the stock a “hold” rating in a report on Wednesday, February 21st. Cantor Fitzgerald set a $25.00 price target on shares of Valeant Pharmaceuticals International and gave the stock a “buy” rating in a report on Wednesday, February 28th. Wells Fargo reissued a “sell” rating on shares of Valeant Pharmaceuticals International in a report on Monday, March 12th. Mizuho raised shares of Valeant Pharmaceuticals International from an “underperform” rating to a “neutral” rating and boosted their price target for the stock from $10.00 to $15.00 in a report on Friday, April 6th. Finally, Zacks Investment Research downgraded shares of Valeant Pharmaceuticals International from a “hold” rating to a “strong sell” rating in a report on Saturday, January 13th. Five equities research analysts have rated the stock with a sell rating, twelve have given a hold rating, six have given a buy rating and one has given a strong buy rating to the company’s stock. Valeant Pharmaceuticals International has an average rating of “Hold” and a consensus price target of $18.56.
Valeant Pharmaceuticals International (NYSE:VRX) (TSE:VRX) last announced its quarterly earnings results on Wednesday, February 28th. The specialty pharmaceutical company reported $0.98 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.96 by $0.02. Valeant Pharmaceuticals International had a return on equity of 42.48% and a net margin of 27.56%. The firm had revenue of $2.16 billion for the quarter, compared to analysts’ expectations of $2.18 billion. During the same period in the prior year, the business posted $1.26 earnings per share. The company’s revenue was down 10.0% on a year-over-year basis. sell-side analysts predict that Valeant Pharmaceuticals International will post 3.12 earnings per share for the current fiscal year.
In related news, Director Schutter Richard U. De purchased 10,000 shares of the firm’s stock in a transaction dated Thursday, March 8th. The shares were purchased at an average cost of $15.34 per share, for a total transaction of $153,400.00. Following the completion of the transaction, the director now directly owns 106,062 shares in the company, valued at approximately $1,626,991.08. The acquisition was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director John Paulson purchased 7,066,629 shares of the firm’s stock in a transaction dated Tuesday, March 6th. The shares were bought at an average price of $15.40 per share, for a total transaction of $108,826,086.60. The disclosure for this purchase can be found here. Over the last quarter, insiders have bought 7,121,629 shares of company stock worth $109,702,487. Company insiders own 11.54% of the company’s stock.
Valeant Pharmaceuticals International Company Profile
Valeant Pharmaceuticals International, Inc is a pharmaceutical and medical device company. The Company is engaged in developing and marketing a range of branded, generic and branded generic pharmaceuticals, over-the-counter (OTC) products, and medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment, and aesthetics devices).
Receive News & Ratings for Valeant Pharmaceuticals International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Valeant Pharmaceuticals International and related companies with MarketBeat.com's FREE daily email newsletter.